Meta‑analysis of the efficacy and safety of nifekalant in the conversion of atrial fibrillation

Atrial fibrillation (AF) is the most common type of supraventricular tachyarrhythmia. Nifekalant is a new class III antiarrhythmic drug approved for the treatment of ventricular tachyarrhythmias, but its effectiveness in converting AF to sinus rhythm remains unclear. The present analysis aimed to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Peng, Li, Kaiyuan, Wang, Shuya, Liu, Miao, Wang, Lei, Su, Guohai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780521/
https://www.ncbi.nlm.nih.gov/pubmed/36588807
http://dx.doi.org/10.3892/etm.2022.11755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780521/
https://www.ncbi.nlm.nih.gov/pubmed/36588807
http://dx.doi.org/10.3892/etm.2022.11755

Ejemplares similares